Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK to Acquire Aiolos Bio for $1B Upfront | Contract Pharma

What are you searching for?

Sign in
Breaking News

GSK to Acquire Aiolos Bio for $1B Upfront

Provides access to Aiolos’ AIO-001, a potential best-in-class monoclonal antibody ready to enter phase II development for the treatment of asthma.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GSK plc entered into an agreement to acquire Aiolos Bio, Inc., a clinical-stage biopharmaceutical company focused on treatments for certain respiratory and inflammatory conditions, for a $1 billion upfront and as much as $400 million in success-based regulatory milestones.
 
The acquisition provides GSK with access to Aiolos’ AIO-001, a potential best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II development for the treatment of asthma, with potential for additional indications including chronic rhinosinusitis with nasal polyps. AIO-001 was exclusively licensed to Aiolos outside of Greater China by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
 
Targeting the TSLP pathway addresses a key driver of the inflammatory response in major allergic and inflammatory diseases. TSLP is a clinically validated target in the treatment of asthma regardless of biomarker status. Early studies of AIO-001 have shown initial safety, tolerability, pharmacokinetics, and biological activity in healthy volunteers and asthma patients. Additionally, AIO-001 has potential to be administered every six months due to its enhanced potency and half-life extension technology.
 
With AIO-001, GSK’s respiratory portfolio could provide the option of a biologic to a broader portion of the 315 million patients living with asthma regardless of biomarker status and including those with low T2 inflammation.

Tony Wood, Chief Scientific Officer, GSK, said, “We have a proud heritage and deep development expertise in respiratory medicines, especially addressing diseases driven by IL-5 with high levels of eosinophils or high T2 inflammation. Adding AIO-001, a potentially best-in-class medicine targeting the TSLP pathway, could expand the reach of our current respiratory biologics portfolio, including to the 40% of severe asthma patients with low T2 inflammation where treatment options are still needed.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics